Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Apyx Medical announces FDA 510k submission for use of renuvion » 07:34
06/01/21
06/01
07:34
06/01/21
07:34
APYX

Apyx Medical

$9.79 /

-0.14 (-1.41%)

Apyx Medical announced it…

Apyx Medical announced it has submitted a 510k premarket notification to the Food and Drug Administration, which is intended to obtain a specific clinical indication for the use of Renuvion in dermal resurfacing procedures. "Following the recent completion of our U.S. IDE clinical study evaluating the use of our Renuvion technology in dermal resurfacing procedures, we were pleased to submit our 510k premarket notification for this procedure category on May 28th," said Charlie Goodwin, President and CEO. "This submission is an important milestone that underscores our continued progress in pursuing specific clinical indications to market and sell Renuvion for target procedures in the cosmetic surgery market. I would like to thank our clinical and regulatory teams for their exceptional efforts which has made our recent progress possible, and look forward to the FDA's review of our submission."

ShowHide Related Items >><<
APYX Apyx Medical
$9.79 /

-0.14 (-1.41%)

05/12/21 Piper Sandler
Piper Sandler remains buyer of Apyx Medical after 'solid' Q1
03/31/21 Piper Sandler
Apyx Medical set up well for continued growth, says Piper Sandler
01/29/21 Piper Sandler
Apyx Medical price target raised to $12 from $8 at Piper Sandler
06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
APYX Apyx Medical
$9.79 /

-0.14 (-1.41%)

APYX Apyx Medical
$9.79 /

-0.14 (-1.41%)

Over a month ago
Recommendations
Piper Sandler remains buyer of Apyx Medical after 'solid' Q1 » 10:44
05/12/21
05/12
10:44
05/12/21
10:44
APYX

Apyx Medical

$9.41 /

-0.11 (-1.16%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien reiterates an Overweight rating on Apyx Medical with a $12 price target citing this morning's "solid beat and raise" quarter. While generator sales are still seeing some lingering impacts from the pandemic, the business grew over 80% year-over-year, with global hand piece sales also strong, growing over 100%, O'Brien tells investors in a research note. The analyst thinks Apyx is set up well for "continued acceleration over the coming years" and he views the current valuation as "reasonable." O'Brien sees a "lot to like with this name" and remains a buyer of the stock.

ShowHide Related Items >><<
APYX Apyx Medical
$9.41 /

-0.11 (-1.16%)

APYX Apyx Medical
$9.41 /

-0.11 (-1.16%)

03/31/21 Piper Sandler
Apyx Medical set up well for continued growth, says Piper Sandler
01/29/21 Piper Sandler
Apyx Medical price target raised to $12 from $8 at Piper Sandler
06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
APYX Apyx Medical
$9.41 /

-0.11 (-1.16%)

APYX Apyx Medical
$9.41 /

-0.11 (-1.16%)

Earnings
Apyx Medical sees FY21 revenue in the range of $37.6M-39.7M, consensus $37.82M  07:14
05/12/21
05/12
07:14
05/12/21
07:14
APYX

Apyx Medical

$9.52 /

+0.34 (+3.70%)

 
ShowHide Related Items >><<
APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

03/31/21 Piper Sandler
Apyx Medical set up well for continued growth, says Piper Sandler
01/29/21 Piper Sandler
Apyx Medical price target raised to $12 from $8 at Piper Sandler
06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

Earnings
Apyx Medical reports Q1 EPS (14c) consensus (14c) » 07:11
05/12/21
05/12
07:11
05/12/21
07:11
APYX

Apyx Medical

$9.52 /

+0.34 (+3.70%)

Reports Q1 revenue $8.6M,…

Reports Q1 revenue $8.6M, consensus $7.84M. "I would like to commend our team on their exceptional efforts during the quarter, which enabled us to achieve first quarter revenue results that exceeded our expectations, driven by strong global sales of our Advanced Energy products," said Charlie Goodwin, President and Chief Executive Officer. "In spite of the continued impacts of the COVID-19 pandemic, we continued to see healthy utilization of our Helium Plasma Technology in the U.S. and key international markets, resulting in total handpiece growth in excess of 100% year-over-year. We were also excited to see global generator sales increase by more than 80% year-over-year, which was driven by strong demand in both the U.S. and our existing international markets. Importantly, we complemented our strong global sales performance in the first quarter with notable margin improvements, due in part to our efforts to reduce the per unit manufacturing costs of our Advanced Energy handpieces and managing our discretionary spending appropriately given the current operating environment."

ShowHide Related Items >><<
APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

03/31/21 Piper Sandler
Apyx Medical set up well for continued growth, says Piper Sandler
01/29/21 Piper Sandler
Apyx Medical price target raised to $12 from $8 at Piper Sandler
06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

APYX Apyx Medical
$9.52 /

+0.34 (+3.70%)

Recommendations
Apyx Medical set up well for continued growth, says Piper Sandler » 12:23
03/31/21
03/31
12:23
03/31/21
12:23
APYX

Apyx Medical

$9.07 /

-0.92 (-9.21%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien reiterates an Overweight rating on Apyx Medical with a $12 price target following the company's better than expected Q4 results. While domestic generator sales continue to be pressured by the pandemic, international stood out, growing 88% year-over-year, O'Brien tells investors in a research note. The analyst thinks Apyx is set up well for continued growth acceleration of the business over the coming years. "Add in a reasonable valuation, and we think there is a lot to like here," he writes.

ShowHide Related Items >><<
APYX Apyx Medical
$9.07 /

-0.92 (-9.21%)

APYX Apyx Medical
$9.07 /

-0.92 (-9.21%)

01/29/21 Piper Sandler
Apyx Medical price target raised to $12 from $8 at Piper Sandler
06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
APYX Apyx Medical
$9.07 /

-0.92 (-9.21%)

APYX Apyx Medical
$9.07 /

-0.92 (-9.21%)

Earnings
Apyx Medical sees FY21 revenue of $36.7M-$38.7M, consensus $39.15M » 07:08
03/31/21
03/31
07:08
03/31/21
07:08
APYX

Apyx Medical

$9.99 /

+0.305 (+3.15%)

Adjusted EBITDA loss in…

Adjusted EBITDA loss in the range of $14.6 M $12M compared to adjusted EBITDA loss of $14.5M for the year ended December 31..

ShowHide Related Items >><<
APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

01/29/21 Piper Sandler
Apyx Medical price target raised to $12 from $8 at Piper Sandler
06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

Earnings
Apyx Medical reports Q4 EPS (4c), consensus (11c) » 07:04
03/31/21
03/31
07:04
03/31/21
07:04
APYX

Apyx Medical

$9.99 /

+0.305 (+3.15%)

Reports Q4 revenue…

Reports Q4 revenue $11.5M, consensus $9.62M. Our team brought 2020 to a strong finish by achieving 44% year-over-year revenue growth in the fourth quarter, despite the continued impacts related to the COVID-19 pandemic," said Charlie Goodwin, President and Chief Executive Officer. "In the fourth quarter, we were pleased to see strong, utilization-based demand in the U.S., with handpiece sales increasing 80%, coupled with 75% year-over-year growth in handpiece sales to our international customers. While demand for our generators in the U.S. continued to be affected by the softer capital equipment purchasing environment due to COVID-19, international generator sales increased 88% year-over-year, driven by demand from several of the new countries that we entered during 2020. In addition to our strong sales performance, we also reported solid margin improvements driven by our efforts to reduce the per unit manufacturing costs of our Advanced Energy handpieces, as well as our focus on reducing discretionary spending in response to the challenging operating environment. Lastly, we delivered important progress with respect to our two U.S. IDE clinical studies, which are designed support our pursuit of new clinical indications for target cosmetic surgery procedures."

ShowHide Related Items >><<
APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

01/29/21 Piper Sandler
Apyx Medical price target raised to $12 from $8 at Piper Sandler
06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

APYX Apyx Medical
$9.99 /

+0.305 (+3.15%)

Over a quarter ago
Recommendations
Apyx Medical price target raised to $12 from $8 at Piper Sandler » 05:07
01/29/21
01/29
05:07
01/29/21
05:07
APYX

Apyx Medical

$9.45 /

+0.09 (+0.96%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on Apyx Medical to $12 from $8 and keeps an Overweight rating on the shares. The analyst adjusted targets in the medical technology and devices space.

ShowHide Related Items >><<
APYX Apyx Medical
$9.45 /

+0.09 (+0.96%)

APYX Apyx Medical
$9.45 /

+0.09 (+0.96%)

06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
APYX Apyx Medical
$9.45 /

+0.09 (+0.96%)

APYX Apyx Medical
$9.45 /

+0.09 (+0.96%)

On The Fly
Fly Intel: After-Hours Movers » 18:23
01/13/21
01/13
18:23
01/13/21
18:23
PFSW

PFSweb

$7.21 /

+0.11 (+1.55%)

, ORGO

Organogenesis

$7.34 /

+ (+0.00%)

, APYX

Apyx Medical

$7.94 /

-0.08 (-1.00%)

, JWN

Nordstrom

$37.60 /

+0.325 (+0.87%)

, HWCC

Houston Wire & Cable

$3.03 /

+0.03 (+1.00%)

Check out this evening's…

ShowHide Related Items >><<
PFSW PFSweb
$7.21 /

+0.11 (+1.55%)

ORGO Organogenesis
$7.34 /

+ (+0.00%)

JWN Nordstrom
$37.60 /

+0.325 (+0.87%)

HWCC Houston Wire & Cable
$3.03 /

+0.03 (+1.00%)

APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

PFSW PFSweb
$7.21 /

+0.11 (+1.55%)

12/07/20 B. Riley
Strony holiday sales bode well for PFSweb, says B. Riley Securities
09/30/20 B. Riley
PFSweb selloff brings buying opportunity, says B. Riley Securities
08/10/20 Lake Street
PFSweb price target raised to $9 from $6 at Lake Street
08/03/20 B. Riley
PFSweb price target raised to $9.50 from $7.50 at B. Riley FBR
ORGO Organogenesis
$7.34 /

+ (+0.00%)

03/06/20 Credit Suisse
Organogenesis price target lowered to $8 from $10 at Credit Suisse
APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
JWN Nordstrom
$37.60 /

+0.325 (+0.87%)

12/31/20 Wedbush
Nordstrom price target raised to $35 from $17 at Wedbush
12/11/20 KeyBanc
Nordstrom price target raised to $35 from $30 at KeyBanc
11/25/20 Credit Suisse
Nordstrom price target raised to $26 from $17 at Credit Suisse
11/25/20 Barclays
Nordstrom price target raised to $19 from $12 at Barclays
HWCC Houston Wire & Cable
$3.03 /

+0.03 (+1.00%)

PFSW PFSweb
$7.21 /

+0.11 (+1.55%)

ORGO Organogenesis
$7.34 /

+ (+0.00%)

JWN Nordstrom
$37.60 /

+0.325 (+0.87%)

APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

  • 13
    Nov
JWN Nordstrom
$37.60 /

+0.325 (+0.87%)

ORGO Organogenesis
$7.34 /

+ (+0.00%)

JWN Nordstrom
$37.60 /

+0.325 (+0.87%)

APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

ORGO Organogenesis
$7.34 /

+ (+0.00%)

JWN Nordstrom
$37.60 /

+0.325 (+0.87%)

Earnings
Apyx Medical sees FY20 revenue $27.1M-$27.5M, consensus $24.35M » 16:17
01/13/21
01/13
16:17
01/13/21
16:17
APYX

Apyx Medical

$7.94 /

-0.08 (-1.00%)

The company sees FY 20 …

The company sees FY 20 revenue in a range of approximately $27.1 to $27.5M, down approximately 3% to 4% year-over-year.;Advanced Energy revenue in a range of approximately $21.9 to $22.2M, down approximately 2% to 4% year-over-year. and OEM revenue in a range of approximately $5.25 to $5.35M down approximately 4% to 5% year-over-year.

ShowHide Related Items >><<
APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

APYX Apyx Medical
$7.94 /

-0.08 (-1.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.